Zentalis
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
10275 Science Center Dr Ste 200, San Die...Phone Number
(212) 433-3791Website
www.zentalis.comRevenue
$26.9 MillionStock Symbol
ZNTLIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Zentalis
Zentalis Pharmaceuticals is a biopharmaceutical company focused on developing differentiated therapeutics targeting cancer pathways. Zentalis was founded in 2014 and is headquartered in New York City, New York.Explore more
Zentalis Org Chart
Get the full picture
Sign in to uncover key details.
SL
Executive Director, Clinical Operations
MA
Director Pharmacovigilance
TS
Associate Director, Clinical Operations
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Zentalis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Zentalis had a recent Job posting/layoffs
Check out if Zentalis is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Zentalis recently announced quarterly report
Zentalis, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Zentalis
Funding: Get notified immidiatlly once Zentalis has new funding data
Product Launch: Get notified when Zentalis launches new products
Check if Zentalis has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Zentalis
Find more new buyers
Compare Similar Companies to Zentalis
Compare insights from companies similar to Zentalis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Zentalis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Zentalis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Zentalis.
Zentalis financials insights
Gather financial insights about Zentalis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Stock Offering
$165M
Series A
$20M
2021
Share Placement
$150.4M
Series B
$75M
Zentalis Tech Stack
A closer look at the technologies used by Zentalis
See more technologies
Most Recent Scoops
Open Position
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Business Finance, Finance, Financing & Debt
Hiring Plans
Zentalis has more open roles in Medical & Health than it has had at any time in the past 12 months.
Hiring Plans
Open Position
Zentalis News & Media
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on September 1, 2026, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 269,000 shares of the Company’s common stock to four (4Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment approach for ovarian cancer, today announced that it has closed its previously announced underwritten public offering of 26,450,000 shares of its common stock, including 3,450,000 shares sold pursuant toZentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering
SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment approach for ovarian cancer, today announced the pricing of an underwritten public offering of 23,000,000 shares of its common stock at a public offering price of $3.50 per share. The total gross proceedZentalis Pharmaceuticals Announces Proposed Underwritten Public Offering
SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment approach for ovarian cancer, today announced the commencement of a proposed underwritten public offering of shares of its common stock and in lieu of common stock to certain investors that so choose, pre
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Zentalis
Sign Up For FreeTo access detailed company insights
Zentalis Pharmaceuticals is a biopharmaceutical company focused on developing differentiated therapeutics targeting cancer pathways. Zentalis was founded in 2014 and is headquartered in New York City, New York.... Read More
